Login to Your Account



Imclone legacy drug gains green light for Lilly in soft tissue sarcoma

By Marie Powers
News Editor

Wednesday, October 19, 2016

In 2008, Eli Lilly and Co. picked up the pieces of Imclone Systems Inc. following a failed hostile takeover bid from Bristol-Myers Squibb Co. Olaratumab on Wednesday gained accelerated approval from the FDA to treat adults with soft tissue sarcoma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription